Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid α-glucosidase in a model of glycogen storage disease type II

Human Gene Therapy

Volumn 16, Issue 1, 2005, Pages 68-80

  Cresawn, Kerry O ^a   Fraites Jr , Thomas J ^a   Wasserfall, Clive ^a   Atkinson, Mark ^a   Lewis, Melissa ^a   Porvasnik, Stacy ^a   Liu, Chen ^a   Mah, Cathryn ^a   Byrne, Barry J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE; GLYCOGEN; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CARDIOPULMONARY INSUFFICIENCY; CONTROLLED STUDY; DIAPHRAGM MUSCLE; GLYCOGEN STORAGE DISEASE TYPE 2; HEART MUSCLE; HINDLIMB; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYSOSOME STORAGE DISEASE; MOUSE; MUSCLE CONTRACTILITY; NONHUMAN; SOLEUS MUSCLE; VIRUS GENOME; VIRUS RECOMBINANT;

ALPHA-GLUCOSIDASES; ANIMALS; ANTIBODIES, MONOCLONAL; DEPENDOVIRUS; FEMALE; GENE THERAPY; GENETIC VECTORS; GLUCAN 1,4-ALPHA-GLUCOSIDASE; GLYCOGEN; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, ANIMAL; MUSCLE, SKELETAL; MYOCARDIUM;

EID: 13844264229     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.68     Document Type: Article

References (40)

1. BEATY, R.M., JACKSON, M., PETERSON, D., BIRD, A., BROWN, T., BENJAMIN, D.K., JR., JUOPPERI, T., KISHNANI, P., BONEY, A., CHEN, Y.T., and KOEBERL, D.D. (2002). Delivery of glucose-6-phosphatase in a canine model for glycogen storage disease, type Ia, with adeno-associated virus (AAV) vectors. Gene Ther. 9, 1015-1022.
2. BERNS, K.I., and LINDEN, R.M. (1995). The cryptic life style of adeno-associated virus. Bioessays 17, 237-245.
3. BROCKSTEDT, D.G., PODSAKOFF, G.M., FONG, L., KURTZMAN, G., MUELLER-RUCHHOLTZ, W., and ENGLEMAN, E.G. (1999). Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin. Immunol. 92, 67-75.
4. BROOKS, D.A. (1999). Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol. Genet. Metab. 68, 268-275.
5. CORDIER, L., GAO, G.P., HACK, A.A., McNALLY, E.M., WILSON, J.M., CHIRMULE, N., and SWEENEY, H.L. (2001). Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum. Gene Ther. 12, 205-215.
6. DALY, T.M., OHLEMILLER, K.K., ROBERTS, M.S., VOGLER, C.A., and SANDS, M.S. (2001). Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Ther. 8, 1291-1298.
7. DING, E., HU, H., HODGES, B.L., MIGONE, F., SERRA, D., XU, F., CHEN, Y.T., and AMALFITANO, A. (2002). Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. Mol. Ther. 5, 436-446.
8. DING, E.Y., HODGES, B.L., HU, H., MCVIE-WYLIE, A.J., SERRA, D., MIGONE, F.K., PRESSLEY, D., CHEN, Y.T., and AMALFITANO, A. (2001). Long-term efficacy after [E1-, polymerase-] adenovirus-mediated transfer of human acid-α-glucosidase gene into glycogen storage disease type II knockout mice. Hum. Gene Ther. 12, 955-965.
9. FIELDS, P.A., KOWALCZYK, D.W., ARRUDA, V.R., ARMSTRONG, E., MCCLELAND, M.L., HAGSTROM, J.N., PASI, K.J., ERTL, H.C., HERZOG, R.W., and HIGH, K.A. (2000). Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol. Ther. 1, 225-235.
10. FIELDS, P.A., ARRUDA, V.R., ARMSTRONG, E., CHU, K., MINGOZZI, F., HAGSTROM, J.N., HERZOG, R.W., and HIGH, K.A. (2001). Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol. Ther. 4, 201-210.
11. FLOTTE, T.R., ZEITLIN, P.L., REYNOLDS, T.C., HEALD, A.E., PEDERSEN, P., BECK, S., CONRAD, C.K., BRASS-ERNST, L., HUMPHRIES, M., SULLIVAN, K., WETZEL, R., TAYLOR, G., CARTER, B.J., and GUGGINO, W.B. (2003). Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: A two-part clinical study. Hum. Gene Ther. 14, 1079-1088.
12. FRAITES, T.J., JR., SCHLEISSING, M.R., SHANELY, R.A., WALTER, G.A., CLOUTIER, D.A., ZOLOTUKHIN, I., PAULY, D.F., RABEN, N., PLOTZ, P.H., POWERS, S.K., KESSLER, P.D., and BYRNE, B.J. (2002). Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol. Ther. 5, 571-578.
13. HERZOG, R.W., FIELDS, P.A., ARRUDA, V.R., BRUBAKER, J.O., ARMSTRONG, E., MCCLINTOCK, D., BELLINGER, D.A., COUTO, L.B., NICHOLS, T.C., and HIGH, K.A. (2002). Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum. Gene Ther. 13, 1281-1291.
14. HIGH, K.A. (2003). Gene transfer as an approach to treating hemophilia. Semin. Thromb. Hemost. 29, 107-120.
15. HIRSCHHORN, R., and REUSER, A.J.J. (2000). Glycogen storage disease II: Acid-α glucosidase (acid maltase) deficiency. In The Metabolic and Molecular Bases of Inherited Disease. C.R. Scriver, A.L. Beaudet, D. Valle, and W.S. Sly, eds. (McGraw-Hill, New York) pp. 3389-3420.
16. HOEFSLOOT, L.H., WILLEMSEN, R., KROOS, M.A., HOOGEVEEN-WESTERVELD, M., HERMANS, M.M., VAN DER PLOEG, A.T., OOSTRA, B.A., and REUSER, A.J. (1990). Expression and routing of human lysosomal α-glucosidase in transiently transfected mammalian cells. Biochem. J. 272, 485-492.
17. JUNG, S.C., HAN, I.P., LIMAYE, A., XU, R., GELDERMAN, M.P., ZERFAS, P., TIRUMALAI, K., MURRAY, G.J., DURING, M.J., BRADY, R.O., and QASBA, P. (2001). Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc. Natl. Acad. Sci. U.S.A. 98, 2676-2681.
18. LIU, C., CONDREAY, L.D., BURCH, J.B., and MASON, W. (1991). Characterization of the core promoter and enhancer of duck hepatitis B virus. Virology 184, 242-252.
19. LIU, D.W., TSAO, Y.P., HSIEH, C.H., HSIEH, J.T., KUNG, J.T., CHIANG, C.L., HUANG, S.J., and CHEN, S.L. (2000). Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. J. Virol. 74, 9083-9089.
20. LO, W.D., QU, G., SFERRA, T.J., CLARK, R., CHEN, R., and JOHNSON, P.R. (1999). Adeno-associated virus-mediated gene transfer to the brain: Duration and modulation of expression. Hum. Gene Ther. 10, 201-213.
21. MANNING, W.C., PALIARD, X., ZHOU, S., PAT, B.M., LEE, A.Y., HONG, K., WALKER, C.M., ESCOBEDO, J.A., and DWARKI, V. (1997). Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. J. Virol. 71, 7960-7962.
22. MINGOZZI, F., LIU, Y.L., DOBRZYNSKI, E., KAUFHOLD, A., LIU, J.H., WANG, Y., ARRUDA, V.R., HIGH, K.A., and HERZOG, R.W. (2003). Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin. Invest. 111, 1347-1356.
23. MOUNT, J.D., HERZOG, R.W., TILLSON, D.M., GOODMAN, S.A., ROBINSON, N., MCCLELAND, M.L., BELLINGER, D., NICHOLS, T.C., ARRUDA, V.R., LOTHROP, C.D., Jr., and HIGH, K.A. (2002). Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 99, 2670-2676.
24. PAULY, D.F., JOHNS, D.C., MATELIS, L.A., LAWRENCE, J.H., BYRNE, B.J., and KESSLER, P.D. (1998). Complete correction of acid α-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle. Gene Ther. 5, 473-480.
25. RABEN, N., NAGARAJU, K., LEE, E., KESSLER, P., BYRNE, B., LEE, L., LAMARCA, M., KING, C., WARD, J., SAUER, B., and PLOTZ, P. (1998). Targeted disruption of the acid α-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J. Biol. Chem. 273, 19086-19092.
26. RABEN, N., LU, N., NAGARAJU, K., RIVERA, Y., LEE, A., YAN, B., BYRNE, B., MEIKLE, P.J., UMAPATHYSIVAM, K., HOPWOOD, J.J., and PLOTZ, P.H. (2001). Conditional tissue-specific expression of the acid α-glucosidase (GAA) gene in the GAA knock-out mice: Implications for therapy. Hum. Mol. Genet. 10, 2039-2047.
27. RABEN, N., PLOTZ, P., and BYRNE, B.J. (2002). Acid α-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr. Mol. Med. 2, 145-166.
28. RABEN, N., DANON, M., GILBERT, A.L., DWIVEDI, S., COLLINS, B.. THURBERG, B.L., MATTALIANO, R.J., NAGARAJU, K., and PLOTZ, P.H. (2003a). Enzyme replacement therapy in the mouse model of Pompe disease. Mol. Genet. Metab. 80, 159-169.
29. RABEN, N., NAGARAJU, K., LEE, A., LU, N., RIVERA, Y., JATKAR, T., HOPWOOD, J.J., and PLOTZ, P.H. (2003b). Induction of tolerance to a recombinant human enzyme, acid α-glucosidase, in enzyme deficient knockout mice. Transgenic Res. 12, 171-178.
30. REUSER, A.J., KROOS, M.A., HERMANS, M.M., BIJVOET, A.G., VERBEET, M.P., VAN DIGGELEN, O.P., KLEIJER, W.J., and VAN DER PLOEG, A.T. (1995). Glycogenosis type II (acid maltase deficiency). Muscle Nerve 3, S61-S69.
31. SUN, B.D., CHEN, Y.T., BIRD, A., AMALFITANO, A., and KOEBERL, D.D. (2003). Long-term correction of glycogen storage disease type II with a hybrid Ad-AAV vector. Mol. Ther. 7, 193-201.
32. TAKAHASHI, H., HIRAI, Y., MIGITA, M., SEINO, Y., FUKUDA, Y., SAKURABA, H., KASE, R., KOBAYASHI, T., HASHIMOTO, Y., and SHIMADA, T. (2002). Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc. Natl. Acad. Sci. U.S.A. 99, 13777-13782.
33. VANDENDRIESSCHE, T., COLLEN, D., and CHUAH, M.K. (2003). Gene therapy for the hemophilias. J. Thromb. Haemost. 1, 1550-1558.
34. WEI, J.F., WEI, F.S., SAMULSKI, R.J., and BARRANGER, J.A. (1994). Expression of the human glucocerebrosidase and arylsulfatase A genes in murine and patient primary fibroblasts transduced by an adeno-associated virus vector. Gene Ther. 1, 261-268.
35. WISSELAAR, H.A., KROOS, M.A., HERMANS, M.M., VAN BEEUMEN, J., and REUSER, A.J. (1993). Structural and functional changes of lysosomal acid α-glucosidase during intracellular transport and maturation. J. Biol. Chem. 268, 2223-2231.
36. XIN, K.Q., URABE, M., YANG, J., NOMIYAMA, K., MIZUKAMI, H., HAMAJIMA, K., NOMIYAMA, H., SAITO, T., IMAI, M., MONAHAN, J., OKUDA, K., OZAWA, K., and OKUDA, K. (2001). A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum. Gene Ther. 12, 1047-1061.
37. ZHANG, Y., CHIRMULE, N., GAO, G., and WILSON, J. (2000). CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: Role of immature dendritic cells. J. Virol. 74, 8003-8010.
38. ZIEGLER, R.J., LONNING, S.M., ARMENTANO, D., LI, C., SOUZA, D.W., CHERRY, M., FORD, C., BARBON, C.M., DESNICK, R.J., GAO, G., WILSON, J.M., PELUSO, R., GODWIN, S., CARTER, B.J., GREGORY, R.J., WADSWORTH, S.C., and CHENG, S.H. (2004). AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of α-galactosidase A and the induction of immune tolerance in Fabry mice. Mol. Ther. 9, 231-240.
39. ZOLOTUKHIN, S., BYRNE, B.J., MASON, E., ZOLOTUKHIN, I., POTTER, M., CHESNUT, K., SUMMERFORD, C., SAMULSKI, R.J., and MUZYCZKA, N. (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6, 973-985.
40. ZOLOTUKHlN, S., POTTER, M., ZOLOTUKHIN, I., SAKAI, Y., LOILER, S., FRAITES, T.J., JR., CHIODO, V.A., PHILLIPSBERG, T., MUZYCZKA, N., HAUSWIRTH, W.W., FLOTTE, T.R., BYRNE, B.J., and SNYDER, R.O. (2002). Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28, 158-167.